Therapeutic synergy between tigecycline and venetoclax in a preclinical model of MYC/BCL2 double-hit B cell lymphoma

See allHide authors and affiliations

Science Translational Medicine  31 Jan 2018:
Vol. 10, Issue 426, eaan8723
DOI: 10.1126/scitranslmed.aan8723

Doubling up against double-hit lymphoma

Double-hit lymphomas, a type of B cell lymphomas with concurrent activation of the MYC and BCL2 oncogenes, are aggressive and difficult-to-treat tumors. In light of evidence showing that tigecycline, an antibiotic, may be effective against MYC-driven lymphomas, Ravà et al. combined it with venetoclax, a BCL2 inhibitor, to target the double-hit tumors. The authors found that the pair of clinically approved drugs showed synergy against the cancer and was also effective in combination with rituximab, a mainstay of current treatment for lymphoma.

View Full Text

Stay Connected to Science Translational Medicine